Designing Novel Apolipoprotein A1 Mimetic Peptides As Drug Treatment For Atherosclerosis
Funder
National Health and Medical Research Council
Funding Amount
$60,016.00
Summary
Cardiovascular disease is the formation of atherosclerotic plaques caused by the imbalance between the amount of cholesterol delivered and removed from the arteries. Apolipoprotein A-1 (ApoA-1) is the main protein of high density lipoprotein (HDL) and removes cholesterol out of cell. In this project we are aimed at designing and testing new drugs (ApoA1-mimetic peptides) which will elicit the same anti-atherogenic properties as apoA-1, as a therapeutic agent for prevention of atherosclerosis.
Advanced Anti-cancer Activities With Therapeutic Agents That Induce Tumor Cell Apoptosis And Antitumor Immune Responses.
Funder
National Health and Medical Research Council
Funding Amount
$85,701.00
Summary
The aim is to perform pre-clinical studies to identify new therapies for blood cancers. We will utilise three new anti-cancer agents that kill tumor cells and genetically engineered mice that develop cancer. We will determine if these three new agents kill the mouse tumor cells and activate anti-tumor immunity. The combined effect of killing blood cancer cells using new therapeutics, coupled with enhancing the anti-cancer immune response may hold the key to developing new treatments.
Development Of Small Molecule Isoform-Selective Dynamin Inhibitors
Funder
National Health and Medical Research Council
Funding Amount
$85,526.00
Summary
Dynamin has roles in nerve cell communication and in cell division. There are 3 dynamin genes: dynamin I in brain; dynamin II in all cells; and dynamin III in brain and testes. Determination of potential selectivity of small molecule dynamin inhibitors for each dynamin gene can provide a basis for the development of new antiepileptic drugs which are specific for dynamin I and thus neuronal tissues, as well as new anticancer drugs that target dynamin II in nonneuronal cells.
Regulation Of Inflammation And Thrombosis By Endothelial Protein C Receptor And Thrombomodulin In Xenograft Rejection
Funder
National Health and Medical Research Council
Funding Amount
$35,085.00
Summary
Pig-to-human organ transplantation may be the solution to the human organ shortage crisis. However, cross-species organ transplantation invariably results in graft destruction and rejection. Genetically modified mice expressing anti-rejection proteins will be tested to assess their effects and benefits on grafts. If such genes improve graft outcome, pigs with similar genetic modifications will be generated for the purposes of pig-to-primate organ transplantation studies.